Eyenovia Vision
Everyday we are making it possible…
Everyday we are making it possible…
We’re achieving microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using our high-precision targeted ocular delivery system, branded the Optejet®, which has the potential to replace conventional eyedropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Our first FDA-approved product, MydCombi, validates the Optejet technology as the next step forward in drug delivery advancement.
In the clinic, Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than traditional eye drops (~ 90% vs. ~ 50%)1,2.
The Optejet also delivers up to a 75-80% reduction in ocular drug and preservative exposure3 and has demonstrated significant improvement in the therapeutic index in drugs used for mydriasis and IOP lowering through three Phase II and Phase III trials4,5. Using the Optejet, we are developing the next generation of smart ophthalmic therapeutics that target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration, or the (FDA).
Our portfolio and pipeline are currently focused on the commercialization and development of microdosed medications for mydriasis, progressive myopia, glaucoma, dry eye, and presbyopia, and consumer-focused therapies.
1. Rathi, S and Scott, B. 2020, May. Evaluation of Topical Ophthalmic Medication Administration Using a Microdose Dispenser ( MiDD ) in Multiple Controlled Clinical Trials.
2. Naito, Tomoko et al. “Comparison of success rates in eye drop instillation between sitting position and supine position.” PloS one vol. 13,9 e0204363. 20 Sep. 2018, doi:10.1371/journal.pone.0204363.
3. American Academy of Ophthalmology (AAO). “Wouldn’t it be great if eyedrops didn’t spill out of your eyes?.” ScienceDaily. ScienceDaily, 13 November 2017.
4. Walters, Thomas. “Clinical Evaluation of a Micro-Dosed Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution for Dilation of the Pupil in Two Randomized, Controlled Phase 3 Trials (MIST-1 & MIST-2).” Eyenovia, Inc., 2019.
5. Pasquale LR, et al. Clin Ophthalmol . 2018;12:2451 2457.